4.50
price up icon0.00%   0.00
after-market Dopo l'orario di chiusura: 4.50
loading
Precedente Chiudi:
$4.50
Aprire:
$4.41
Volume 24 ore:
70,450
Relative Volume:
0.76
Capitalizzazione di mercato:
$229.40M
Reddito:
-
Utile/perdita netta:
$-103.21M
Rapporto P/E:
-0.9782
EPS:
-4.6001
Flusso di cassa netto:
$-26.70M
1 W Prestazione:
+4.65%
1M Prestazione:
-22.28%
6M Prestazione:
-32.13%
1 anno Prestazione:
-72.56%
Intervallo 1D:
Value
$4.30
$4.6579
Intervallo di 1 settimana:
Value
$4.00
$4.6579
Portata 52W:
Value
$4.00
$16.75

Engene Holdings Inc Stock (ENGN) Company Profile

Name
Nome
Engene Holdings Inc
Name
Telefono
(514) 332-4888
Name
Indirizzo
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Name
Dipendente
57
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
ENGN's Discussions on Twitter

Confronta ENGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ENGN
Engene Holdings Inc
4.50 229.40M 0 -103.21M -26.70M -4.6001
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-18 Iniziato Piper Sandler Overweight
2025-02-14 Downgrade UBS Buy → Neutral
2024-12-23 Iniziato H.C. Wainwright Buy
2024-11-27 Iniziato Raymond James Outperform
2024-11-18 Iniziato JMP Securities Mkt Outperform
2024-08-28 Iniziato Oppenheimer Outperform
2024-04-22 Iniziato Wells Fargo Overweight
2024-04-15 Iniziato Guggenheim Buy
2024-03-28 Iniziato UBS Buy
2024-03-08 Iniziato Morgan Stanley Overweight
2024-02-20 Iniziato Leerink Partners Outperform
Mostra tutto

Engene Holdings Inc Borsa (ENGN) Ultime notizie

pulisher
08:03 AM

Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

08:03 AM
pulisher
08:00 AM

enGene Expands Team with New Hires, Grants 144,650 Shares in Stock Options - Stock Titan

08:00 AM
pulisher
Apr 01, 2025

Strategic Oncology Updates Coming: enGene CEO Headlines Stifel Healthcare Forum - Stock Titan

Apr 01, 2025
pulisher
Mar 15, 2025

How the (ENGN) price action is used to our Advantage - news.stocktradersdaily.com

Mar 15, 2025
pulisher
Mar 12, 2025

Promising Trajectory and Strong Financial Position Justify Buy Rating for enGene Holdings - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

enGene Holdings Insider Ups Holding During Year - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

enGene Holdings Inc.'s (NASDAQ:ENGN) market cap dropped US$33m last week; individual investors who hold 38% were hit as were institutions - Simply Wall St

Mar 12, 2025
pulisher
Mar 12, 2025

enGene’s (ENGN) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

enGene (NASDAQ:ENGN) Price Target Lowered to $34.00 at Morgan Stanley - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Engene stock holds Buy rating, $25 target from H.C. Wainwright - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Engene stock holds Buy rating, $25 target from H.C. Wainwright By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

enGene Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace

Mar 11, 2025
pulisher
Mar 10, 2025

enGene Holdings Inc. SEC 10-Q Report - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

enGene Reports Q1 Results: Strong Cash Position Funds Global Trial Expansion - StockTitan

Mar 10, 2025
pulisher
Mar 04, 2025

Trading (ENGN) With Integrated Risk Controls - Stock Traders Daily

Mar 04, 2025
pulisher
Mar 04, 2025

enGene to Participate in the Leerink Partners Global Healthcare Conference - Business Wire

Mar 04, 2025
pulisher
Mar 04, 2025

What Will enGene Reveal? CEO's Upcoming Fireside Chat at Major Healthcare Conference - Stock Titan

Mar 04, 2025
pulisher
Feb 27, 2025

Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

enGene Holdings Inc.: Unknown Company Which Looks Like A Catch (NASDAQ:ENGN) - Seeking Alpha

Feb 27, 2025
pulisher
Feb 25, 2025

Financial Contrast: enGene (NASDAQ:ENGN) versus iTeos Therapeutics (NASDAQ:ITOS) - Defense World

Feb 25, 2025
pulisher
Feb 22, 2025

(ENGN) On The My Stocks Page - Stock Traders Daily

Feb 22, 2025
pulisher
Feb 22, 2025

Vontobel Holding Ltd. Makes New $69,000 Investment in enGene Holdings Inc. (NASDAQ:ENGN) - Defense World

Feb 22, 2025
pulisher
Feb 22, 2025

enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Feb 22, 2025
pulisher
Feb 20, 2025

enGene (NASDAQ:ENGN) Coverage Initiated at Piper Sandler - Armenian Reporter

Feb 20, 2025
pulisher
Feb 19, 2025

enGene Holdings GAAP EPS of -$0.38 - MSN

Feb 19, 2025
pulisher
Feb 19, 2025

New Strong Buy Stocks for February 19th - Zacks Investment Research

Feb 19, 2025
pulisher
Feb 19, 2025

enGene (NASDAQ:ENGN) Now Covered by Piper Sandler - Defense World

Feb 19, 2025
pulisher
Feb 19, 2025

Best Momentum Stocks to Buy for February 19th - Yahoo Finance

Feb 19, 2025
pulisher
Feb 19, 2025

enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of “Buy” by Brokerages - Defense World

Feb 19, 2025
pulisher
Feb 18, 2025

Piper Sandler sets $26 target on Engene shares with Overweight rating - Investing.com Australia

Feb 18, 2025
pulisher
Feb 18, 2025

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Feb 18, 2025
pulisher
Feb 18, 2025

Buy Rating for enGene Holdings: Strategic Positioning and Growth Potential in NMIBC Market - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Piper Sandler Initiates Coverage on enGene Holdings With Overweight Rating, $26 Price Target - Marketscreener.com

Feb 18, 2025
pulisher
Feb 18, 2025

Piper Sandler sets $26 target on Engene shares with Overweight rating By Investing.com - Investing.com South Africa

Feb 18, 2025
pulisher
Feb 17, 2025

Analyzing Ratios: enGene Holdings Inc (ENGN)’s Financial Story Unveiled - The Dwinnex

Feb 17, 2025
pulisher
Feb 16, 2025

enGene (NASDAQ:ENGN) Stock Rating Lowered by UBS Group - Defense World

Feb 16, 2025
pulisher
Feb 15, 2025

enGene (NASDAQ:ENGN) Downgraded to Neutral Rating by UBS Group - MarketBeat

Feb 15, 2025
pulisher
Feb 14, 2025

Sector Update: Health Care -February 14, 2025 at 03:41 pm EST - Marketscreener.com

Feb 14, 2025
pulisher
Feb 14, 2025

EnGene Holdings Shares Fall After UBS Downgrade -February 14, 2025 at 02:55 pm EST - Marketscreener.com

Feb 14, 2025
pulisher
Feb 14, 2025

UBS Downgrades enGene Holdings to Neutral From Buy, Cuts Price Target to $7 From $34 - Marketscreener.com

Feb 14, 2025
pulisher
Feb 14, 2025

enGene downgraded to Neutral from Buy at UBS - TipRanks

Feb 14, 2025
pulisher
Feb 11, 2025

(ENGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Feb 11, 2025
pulisher
Feb 07, 2025

enGene Holdings Inc (ENGN) vs. Its Peers: A Comparison - The News Heater

Feb 07, 2025
pulisher
Feb 04, 2025

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire

Feb 04, 2025
pulisher
Jan 31, 2025

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire

Jan 31, 2025
pulisher
Jan 31, 2025

Where are the Opportunities in (ENGN) - Stock Traders Daily

Jan 31, 2025
pulisher
Jan 31, 2025

Cancer Biotech enGene Strengthens Team with $1.9M Equity Package as Bladder Cancer Trial Advances - Stock Titan

Jan 31, 2025
pulisher
Jan 30, 2025

ENGNenGene Holdings Inc. Latest Stock News & Market Updates - StockTitan

Jan 30, 2025
pulisher
Jan 30, 2025

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) - Business Wire

Jan 30, 2025
pulisher
Jan 26, 2025

FY2026 EPS Estimates for enGene Boosted by Leerink Partnrs - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Jan 25, 2025

Engene Holdings Inc Azioni (ENGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):